PL371128A1 - Sposób leczenia chorób oczu epoksysteroidowymi antagonistami receptora aldosteronu - Google Patents

Sposób leczenia chorób oczu epoksysteroidowymi antagonistami receptora aldosteronu

Info

Publication number
PL371128A1
PL371128A1 PL02371128A PL37112802A PL371128A1 PL 371128 A1 PL371128 A1 PL 371128A1 PL 02371128 A PL02371128 A PL 02371128A PL 37112802 A PL37112802 A PL 37112802A PL 371128 A1 PL371128 A1 PL 371128A1
Authority
PL
Poland
Prior art keywords
epoxy
receptor antagonists
aldosterone receptor
ophthalmic disorders
treating ophthalmic
Prior art date
Application number
PL02371128A
Other languages
English (en)
Inventor
James W. Aiken
Original Assignee
Pharmacia Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corporation filed Critical Pharmacia Corporation
Publication of PL371128A1 publication Critical patent/PL371128A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
PL02371128A 2001-12-12 2002-12-12 Sposób leczenia chorób oczu epoksysteroidowymi antagonistami receptora aldosteronu PL371128A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34103301P 2001-12-12 2001-12-12

Publications (1)

Publication Number Publication Date
PL371128A1 true PL371128A1 (pl) 2005-06-13

Family

ID=23335987

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02371128A PL371128A1 (pl) 2001-12-12 2002-12-12 Sposób leczenia chorób oczu epoksysteroidowymi antagonistami receptora aldosteronu

Country Status (13)

Country Link
US (1) US7015210B2 (pl)
EP (1) EP1455795A1 (pl)
JP (1) JP2005516914A (pl)
KR (1) KR20040080439A (pl)
CN (1) CN1774251A (pl)
AU (1) AU2002346721A1 (pl)
BR (1) BR0214924A (pl)
CA (1) CA2469616A1 (pl)
IL (1) IL162475A0 (pl)
MX (1) MXPA04005674A (pl)
PL (1) PL371128A1 (pl)
WO (1) WO2003049745A1 (pl)
ZA (1) ZA200404619B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469862A2 (en) * 2002-01-30 2004-10-27 Pharmacia Corporation Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
KR101160780B1 (ko) * 2002-08-29 2012-06-27 산텐 세이야꾸 가부시키가이샤 Ｒｈｏ 키나아제 억제제 및 프로스타글란딘류를 포함하는 녹내장 치료제
WO2004045644A1 (ja) * 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
PT1905452E (pt) 2005-07-12 2013-07-16 Kowa Co Agente para a prevenção ou tratamento do glaucoma
US7799331B2 (en) 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
EP2170343A1 (en) * 2007-05-31 2010-04-07 Joseph Weinstock Treatment of age-related macular degeneration
US8609729B2 (en) * 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
RU2411946C1 (ru) * 2009-07-06 2011-02-20 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Вископротектор для защиты интраокулярных тканей
EP2568986B1 (en) * 2010-05-10 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
EP2582365B1 (en) * 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
WO2016141182A1 (en) 2015-03-03 2016-09-09 Yee Richard W Compositions and methods for treating ocular diseases
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
US20180280414A1 (en) * 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3436475A1 (en) 2016-03-29 2019-02-06 STCube & Co., Inc. Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
US11746152B2 (en) * 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177267A (en) 1963-12-09 1979-12-04 Crown Zellerbach Enhancing tissue penetration of physiologically active steroidal agents with DMSC
US3711602A (en) 1970-10-30 1973-01-16 Crown Zellerbach Corp Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
US4559332A (en) 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4552871A (en) 1983-04-13 1985-11-12 Ciba Geigy Corporation Steroids of the 20-spiroxane series, processes for the manufacture thereof, pharmaceutical preparations containing such compounds and the use of the latter
US4670551A (en) 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
FI902006A7 (fi) 1987-10-21 1990-04-20 Upjohn Co Menetelmä renniini-inhibiittoreiden valmistamiseksi, jotka sisältävät 1-amino-2-hydroksi-2-heterosyklisen etyylitähteen
DE4023369A1 (de) 1990-07-23 1992-01-30 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4203872A1 (de) 1992-02-11 1993-08-12 Thomae Gmbh Dr K Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5529992A (en) 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
AU6039296A (en) 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
US6172054B1 (en) * 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
WO2001087284A2 (en) * 2000-05-11 2001-11-22 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
US20040235809A1 (en) 2000-07-27 2004-11-25 Alexander John C Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure

Also Published As

Publication number Publication date
IL162475A0 (en) 2005-11-20
US20030158162A1 (en) 2003-08-21
EP1455795A1 (en) 2004-09-15
ZA200404619B (en) 2005-06-10
CN1774251A (zh) 2006-05-17
KR20040080439A (ko) 2004-09-18
WO2003049745A1 (en) 2003-06-19
BR0214924A (pt) 2004-11-30
MXPA04005674A (es) 2004-10-15
AU2002346721A1 (en) 2003-06-23
US7015210B2 (en) 2006-03-21
JP2005516914A (ja) 2005-06-09
CA2469616A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
IL162475A0 (en) Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
EP1556047A4 (en) ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
IL157770A0 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
AU2003239489A8 (en) Method of treating dyslipidemic disorders
AU2003286611A8 (en) Cytomodulating peptides and methods for treating neurological disorders
EP1471909A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
PL373626A1 (pl) Leczenie zaburzeń centralnego układu nerwowego
IL161041A0 (en) Mch antagonists for the treatment of obesity
HRP20031071A2 (en) Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury
IL157551A0 (en) Ccr5 antagonists useful for treating aids
HUP0501017A3 (en) Methods and compositions for treatment of central nervous system disorders
EP1476147A4 (en) METHODS OF TREATING VIEW DISORDERS
PL373835A1 (pl) Zastosowanie antagonistów CD23 do leczenia choróbnowotworowych
AU2003239280A1 (en) Combination treatment for depression and anxiety by nk1 and nk3 antagonists
AU2001225664A1 (en) 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
ZA200410157B (en) Methods of treating gastrointestinal and genitorinary pain disorders using vanilafaxin and derivatives
PL370746A1 (pl) Pochodne piperazyny do stosowania jako antagoniści receptora CCR-3 w leczeniu astmy
AU2002366217A1 (en) Treatment of major depressive disorder using glucocorticoid receptor antagonists
IL162053A0 (en) Method for the treatment of bone disorders
AU2003247052A1 (en) Mcp-1 receptor antagonists and method of use thereof
AU2003259759A1 (en) Gal3 receptor antagonists for the treatment of affective disorders
PL370367A1 (pl) Antagoniści V receptora CCR-3
EP1503765A4 (en) USE OF NICOTINIC RECEPTOR MODULATORS IN THE TREATMENT OF COGNITIVE DYSFUNCTION
AU2003245995A8 (en) Use of gaba-c receptor antagonists for the treatment of myopia

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)